Highlights From ICAAC 2002
A new study demonstrates the safety of stopping treatment in patients who, when they began antiretroviral therapy, were above today's baseline requirements. Paul Sax, M.D., reports from ICAAC.
"It is exciting to see new drug development with agents that appear at least equally effective as previous agents while less toxic." Edwin DeJesus, M.D., follows up on the pivotal tenofovir 903 trial first presented at Barcelona in July.
Atazanavir (ATV, Zrivada), a once-a-day protease inhibitor in development, continues to show promise in clinical trials. Cal Cohen, M.D., reports on a study that found ATV just as effective in naive patients as the highly touted efavirenz, without causing any lipid abnormalities.
What can clinicians and patients do to manage a regimen that is not fully suppressive? A new study suggests adding tenofovir to the regimen. For the details, read Dr. Cal Cohen's report from ICAAC.
AdvertisementAlthough the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy is over, our expert coverage is still rolling in! Be sure to visit our ICAAC 2002 home page for a fully searchable, browseable rundown of the major HIV/AIDS news from San Diego.
The Body Covers the 2002 Lipodystrophy Conference (ADRL)
It is clear that we have come a long way in understanding the basic scientific mechanisms behind metabolic complications; now it's time to conduct large clinical trials. Pablo Tebas, M.D., gives an overview of the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
For more major developments from this year's International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, be sure to visit ADRL 2002 at The Body.
Food, Sex and Meds: The New Visual AIDS Web Gallery
Three things you might not associate with one another -- food, sexuality and anti-HIV medications -- all meet in October's Visual AIDS Web Gallery.
What's Your Adherence Score?
Currently taking anti-HIV medications? Take this online survey and learn more about how well you're sticking to your regimen!
Tenofovir/ddI Interaction Causes Label Changes
Recently the results of an interaction study of tenofovir (Viread) and once-a-day ddI (Videx EC) were submitted and reviewed. Based on this new study, it was concluded that the magnitude of the interaction between Viread and Videx was significant enough to warrant the inclusion of additional precautionary language in both products' labeling.
Warning on ddI for Those With Hepatitis C
The ddI (didanosine, Videx) product label has been revised to include new, precautionary information about the co-administration of ddI and ribavirin in people coinfected with HIV and hepatitis C. Click here to read more.
HIV Disclosure: All in the Family
Jim Pickett has been sharing his HIV-positive life with the world for seven years, but this month he tells his family what he's never told them before: "Dear Mom, Dad, and Kevin, I have HIV."
Media Turn the Blame on Black MSM
"As more researchers have focused on the startling HIV risk among black gay and bisexual men, some advocates have felt the media has responded to the new data by characterizing black gay men as sexually irresponsible." Charles E. Clifton, Executive Director of Chicago's Test Positive Aware Network, writes about the challenges currently facing gay and bisexual men in the U.S.
HIV: Why Can't the U.S. Control It?
Although the rate of HIV infection is much lower in the U.S. than in the developing world, it's far from being contained. So why is HIV still out of control in a country that has nearly eradicated smallpox, polio and Legionnaire's disease? Test Positive Aware Network's Carlos Perez gives his thoughts.
Sorry, Mr. President: Parents Want Sex Education
A nationwide poll recently conducted of lower-income parents and guardians in the U.S. and released by the Sexuality Information and Education Council of the U.S. (SIECUS) found that parents and guardians overwhelmingly support comprehensive sex education programs that teach young people all aspects of sexuality.
AIDS Vaccines: Just a Matter of Time -- But How Much?
Experts such as Lawrence Corey and Dr. Emilio Emini are confident that a viable HIV vaccine conferring at least partial immunity is within reach. The only question is: Will it take another 17 years?
A Selection of the Top HIV/AIDS Stories From Across the Internet:
HIV Prevention Groups Say Bush Administration Is Targeting Their Work
The U.S. President is accused of conducting a "witch hunt" to eliminate organizations that don't support abstinence-only education
From San Francisco Chronicle (October 1, 2002)
The Next Wave of AIDS: Nigeria, Ethiopia, Russia, India and China (PDF)
Worst-case scenarios expected for China, Ethiopia, India, Nigeria and Russia, with over 50 million HIV cases expected by 2010
From U.S. National Intelligence Council (September 2002)
HIV i-Base Guide to Avoiding & Managing Side Effects
Includes information on alternative treatments and how to talk to your doctor about side effects
From HIV i-Base (August 2002)